$PSTX
Poseida Therapeutics, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021012509 Filed on March 11, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 2019 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.370M $23.03M
YoY Change 72.58% 24.76%
% of Gross Profit
Research & Development $29.10M $103.5M
YoY Change 24.28% 71.41%
% of Gross Profit
Depreciation & Amortization $1.070M $2.600M $730.0K
YoY Change 154.76% 116.67% 386.67%
% of Gross Profit
Operating Expenses $37.46M $126.5M
YoY Change 60.01% 109.54%
Operating Profit -$37.46M -$126.5M
YoY Change 32.53%
Interest Expense $838.0K $3.506M
YoY Change -8.32% -1.32%
% of Operating Profit
Other Income/Expense, Net -$12.00K $280.0K
YoY Change -103.02% -89.06%
Pretax Income -$38.31M -$129.8M
YoY Change 33.11% 49.98%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$38.31M -$129.8M
YoY Change 33.11% 50.01%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$618.1K -$3.605M
COMMON SHARES
Basic Shares Outstanding 62.11M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $270.0M $309.2M
YoY Change 161.12% 146.77%
Cash & Equivalents $169.8M $84.00M $87.78M
Short-Term Investments $100.2M $225.2M
Other Short-Term Assets $4.000M $4.800M
YoY Change -23.08% 166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $274.0M $314.0M $127.2M
YoY Change 152.3% 146.86% 290.12%
LONG-TERM ASSETS
Property, Plant & Equipment $50.20M $48.30M $10.86M
YoY Change 30.39% 343.12% 219.35%
Goodwill $4.228M
YoY Change
Intangibles $1.320M
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.600M $3.600M $3.411M
YoY Change -2.7% 5.88% -2.54%
Total Long-Term Assets $59.30M $57.50M $19.82M
YoY Change 24.32% 190.4% 58.54%
TOTAL ASSETS
Total Short-Term Assets $274.0M $314.0M $127.2M
Total Long-Term Assets $59.30M $57.50M $19.82M
Total Assets $333.3M $371.5M $147.0M
YoY Change 113.24% 152.72% 225.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.500M $800.0K $4.929M
YoY Change -67.53% -83.67% 69.97%
Accrued Expenses $20.40M $27.40M
YoY Change -5.99% 122.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.000M $0.00 $3.000M
YoY Change -50.0% -100.0%
Total Short-Term Liabilities $27.80M $30.00M $21.86M
YoY Change -30.33% 36.99% 68.12%
LONG-TERM LIABILITIES
Long-Term Debt $26.20M $29.10M $26.14M
YoY Change 12.93% 11.49% 36.86%
Other Long-Term Liabilities $51.80M $50.30M $5.421M
YoY Change 9.28% 91.25% -68.48%
Total Long-Term Liabilities $78.00M $79.40M $31.56M
YoY Change 10.48% 51.53% -13.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.80M $30.00M $21.86M
Total Long-Term Liabilities $78.00M $79.40M $31.56M
Total Liabilities $105.9M $109.5M $74.33M
YoY Change -4.16% 47.38% 50.47%
SHAREHOLDERS EQUITY
Retained Earnings -$152.2M
YoY Change
Common Stock $2.691M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $227.5M $262.0M -$149.5M
YoY Change
Total Liabilities & Shareholders Equity $333.3M $371.5M $147.0M
YoY Change 113.24% 152.72% 225.93%

Cashflow Statement

Concept 2021 Q1 2020 2019 Q4
OPERATING ACTIVITIES
Net Income -$38.31M -$129.8M
YoY Change 33.11% 50.01%
Depreciation, Depletion And Amortization $1.070M $2.600M $730.0K
YoY Change 154.76% 116.67% 386.67%
Cash From Operating Activities -$39.06M -$113.3M -$35.74M
YoY Change 70.66% 75.61% 192.71%
INVESTING ACTIVITIES
Capital Expenditures $475.0K $16.91M -$3.210M
YoY Change -86.49% 227.93% 409.52%
Acquisitions
YoY Change
Other Investing Activities $125.0M -$187.5M -$18.66M
YoY Change -5181.3% 402.6%
Cash From Investing Activities $124.5M -$204.4M -$21.86M
YoY Change -2184.8% 381.42% 3369.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 360.0K 313.9M 7.880M
YoY Change -91.72% 91.0% 67.3%
NET CHANGE
Cash From Operating Activities -39.06M -113.3M -35.74M
Cash From Investing Activities 124.5M -204.4M -21.86M
Cash From Financing Activities 360.0K 313.9M 7.880M
Net Change In Cash 85.83M -3.818M -49.72M
YoY Change -450.15% -106.65% 511.56%
FREE CASH FLOW
Cash From Operating Activities -$39.06M -$113.3M -$35.74M
Capital Expenditures $475.0K $16.91M -$3.210M
Free Cash Flow -$39.53M -$130.2M -$32.53M
YoY Change 49.73% 86.88% 180.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
763000
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020Q4 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2020Q4 pstx Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
4738607
CY2020Q4 pstx Authorized For Future Options And Award Grants
AuthorizedForFutureOptionsAndAwardGrants
6403481
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26140000
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Local Phone Number
LocalPhoneNumber
779-3100
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83966000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87784000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
225186000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
37534000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4844000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1861000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
313996000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
127179000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23336000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10858000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24986000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2020Q4 us-gaap Goodwill
Goodwill
4228000
CY2019Q4 us-gaap Goodwill
Goodwill
4228000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3618000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3411000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103520000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Security12b Title
Security12bTitle
Common stock, $0.0001 par value per share
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity File Number
EntityFileNumber
001-39376
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2846548
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
9390 Towne Centre Drive
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2020 dei City Area Code
CityAreaCode
858
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62108168
CY2020Q3 dei Entity Public Float
EntityPublicFloat
516100000
CY2020Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
23755000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
543842000
CY2019Q4 us-gaap Liabilities
Liabilities
74334000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5421000
CY2019Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
19592000
CY2020Q4 us-gaap Liabilities
Liabilities
109516000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29133000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1174000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-86527000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
280000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2559000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-129775000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33085827
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
32934785
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
32934785
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-86527000
CY2020Q4 us-gaap Assets
Assets
371484000
CY2019Q4 us-gaap Assets
Assets
146996000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3050000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
69000
CY2019 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
10596000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4929000
CY2020Q4 pstx Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
24454000
CY2019Q4 pstx Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
13926000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4808000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2019Q4 pstx Warrant Liabilities Noncurrent
WarrantLiabilitiesNoncurrent
1271000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25374000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
222173000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57013463
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61860897
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13196419
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61860897
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13196419
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60393000
CY2019 pstx Business Combination Change In Contingent Consideration Including Related Party Amount
BusinessCombinationChangeInContingentConsiderationIncludingRelatedPartyAmount
6683000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-126549000
CY2020 us-gaap Interest Expense
InterestExpense
3506000
CY2019 us-gaap Interest Expense
InterestExpense
3553000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-129775000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
19000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
19000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129789000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-86508000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.61
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.86
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35996901
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12618413
CY2020 pstx Business Combination Contingent Consideration Related Party Amount
BusinessCombinationContingentConsiderationRelatedPartyAmount
0
CY2019 pstx Business Combination Contingent Consideration Related Party Amount
BusinessCombinationContingentConsiderationRelatedPartyAmount
2739000
CY2020 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2019 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-76718000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
19000
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
224000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
205743000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7220000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
18018000
CY2020 us-gaap Profit Loss
ProfitLoss
-129775000
CY2019 us-gaap Profit Loss
ProfitLoss
-86527000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2586000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1193000
CY2019Q3 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2020-06-26
CY2019Q3 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2019Q3 us-gaap Tenant Improvements
TenantImprovements
2900000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-204431000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42464000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
223000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
69000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
205743000
CY2020 pstx Net Proceeds From Grant
NetProceedsFromGrant
4163000
CY2019 pstx Net Proceeds From Grant
NetProceedsFromGrant
4642000
CY2019 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
10000000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
329000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
53000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
313941000
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-448000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7220000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
3050000
CY2019 pstx Change In Fair Value Of Contingent Liabilities
ChangeInFairValueOfContingentLiabilities
6679000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
387000
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-519000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-805000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-853000
CY2020 pstx Accretion Of Investment Discount Net
AccretionOfInvestmentDiscountNet
174000
CY2019 pstx Accretion Of Investment Discount Net
AccretionOfInvestmentDiscountNet
128000
CY2019 pstx Imputed Rent Expense
ImputedRentExpense
111000
CY2019 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
855000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3296000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-726000
CY2020 pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
3108000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
207000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1676000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4171000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1530000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10320000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7132000
CY2020 pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-131000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1755000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-113328000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64518000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16908000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5156000
CY2020 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
295023000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
71308000
CY2020 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
107500000
CY2019 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
34000000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
164371000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3818000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
57389000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87784000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30395000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83966000
CY2019 pstx Noncash Investing And Financing Activities Issuance Of Common Stock For Acquisition
NoncashInvestingAndFinancingActivitiesIssuanceOfCommonStockForAcquisition
10596000
CY2020 pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
211000
CY2019 pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
1887000
CY2020 pstx Tenant Improvements Receivable From Landlord
TenantImprovementsReceivableFromLandlord
137000
CY2019 pstx Tenant Improvements Receivable From Landlord
TenantImprovementsReceivableFromLandlord
421000
CY2019 us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
2166000
CY2020 pstx Operating Lease Right Of Use Assets And Lease Liabilities
OperatingLeaseRightOfUseAssetsAndLeaseLiabilities
5346000
CY2020 pstx Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering
ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
326313000
CY2019Q3 us-gaap Security Deposit
SecurityDeposit
100000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
3027000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2631000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, which include, but are not limited to, estimates related to accrued expenses, contingent consideration, warrant liability, stock-based compensation expense, deferred tax valuation allowances and, prior to the Company&#8217;s IPO, the fair value of common stock. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants Technical Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation, </font>to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which the Company sold shares of preferred stock and the superior rights, preferences and privileges of the preferred stock relative to the common stock; the Company&#8217;s stage of development and material risks related to its business; the progress of the Company&#8217;s research and development programs, including the status and results of preclinical studies for its product candidates and progress of its development of manufacturing processes; external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#8217;s results of operations and financial position, including its levels of available capital resources, outstanding debt and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock and preferred stock; the likelihood of achieving a liquidity event, such as an IPO or sale of the Company in light of prevailing market conditions; the hiring of key personnel; and the analysis of IPOs and the market performance of publicly traded companies in the biopharmaceutical industry, as well as recently completed mergers and acquisitions of peer companies. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. Deposits held at these institutions may exceed the amount of insurance provided on such deposits.</p>
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106266000
CY2020Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
15822000
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
434000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27931000
CY2019Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
7993000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6793000
CY2020Q4 pstx Prepaid Landlord Reimbursement
PrepaidLandlordReimbursement
137000
CY2019Q4 pstx Prepaid Landlord Reimbursement
PrepaidLandlordReimbursement
421000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3283000
CY2019Q4 pstx Accrued Lease Cancellation Fee Payable Current
AccruedLeaseCancellationFeePayableCurrent
979000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1839000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1671000
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
217000
CY2019Q4 us-gaap Prepaid Rent
PrepaidRent
259000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
295894000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106247000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2226000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
204000
CY2020Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
5000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
19000
CY2020Q4 pstx Prepaid Contract Research Services
PrepaidContractResearchServices
651000
CY2019Q4 pstx Prepaid Contract Research Services
PrepaidContractResearchServices
543000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1613000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
295899000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
309200000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Variable Lease Payment
VariableLeasePayment
0
CY2020Q4 pstx Cash Collateral Held In Bank
CashCollateralHeldInBank
200000
CY2019Q4 pstx Cash Collateral Held In Bank
CashCollateralHeldInBank
200000
CY2020Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
100000
CY2019Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12867000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4595000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2009000
CY2020 us-gaap Depreciation
Depreciation
2600000
CY2019 us-gaap Depreciation
Depreciation
1200000
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1320000
CY2019Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1320000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1271000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
387000
CY2020 pstx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Stockholders Equity Deficit
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInStockholdersEquityDeficit
-1658000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000
CY2020Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
600000
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
46809523
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
42953085
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
42953085
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
6000000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
2500000
CY2020Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
34445108
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
222173000
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
326313000
CY2020Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
326313000
CY2020Q4 pstx Authorized For Future Issuance Under Employee Stock Purchase Plan
AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlan
615000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11757088
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
4800000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
CY2019Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
26411194
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5225000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4333000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.026
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.80
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.86
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.87
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4463000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4597000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
10017000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8226000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2400000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q4 us-gaap Area Of Land
AreaOfLand
83000
CY2020Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P108M
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7220000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3050000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3611030
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1510762
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
219425
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
163760
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4738607
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4738607
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1886521
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.58
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.36
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.02
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.76
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.34
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.34
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.56
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M24D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M2D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y4M2D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M2D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10017000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
23000000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.65
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.47
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6900000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2800000
CY2020 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The manufacturing and laboratory and office space lease agreements include two options to extend the term for a period of 5 years each.
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020 pstx Lessee Operating Lease Number Of Options To Extend Term
LesseeOperatingLeaseNumberOfOptionsToExtendTerm
2
CY2016Q1 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2016-06-30
CY2016Q1 pstx Lessee Operating Lease Initial Term Of Contract
LesseeOperatingLeaseInitialTermOfContract
P10Y6M
CY2016Q1 us-gaap Security Deposit
SecurityDeposit
100000
CY2016Q1 pstx Lease Termination Date
LeaseTerminationDate
2019-04-30
CY2016Q1 pstx Lease Termination Fee
LeaseTerminationFee
1500000
CY2016Q1 pstx Lease Termination Fee Number Of Installments
LeaseTerminationFeeNumberOfInstallments
3
CY2016Q1 pstx Lease Termination Fee Term
LeaseTerminationFeeTerm
P1Y6M
CY2018Q4 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2019-04-01
CY2018Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2018Q4 us-gaap Tenant Improvements
TenantImprovements
4200000
CY2020Q4 pstx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1877000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4735000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
20403000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
30182000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q4 pstx Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1295000
CY2020Q4 pstx Deferred Tax Liabilities Acquired Indefinite Lived Intangibles
DeferredTaxLiabilitiesAcquiredIndefiniteLivedIntangibles
369000
CY2019Q4 pstx Deferred Tax Liabilities Acquired Indefinite Lived Intangibles
DeferredTaxLiabilitiesAcquiredIndefiniteLivedIntangibles
369000
CY2020Q4 pstx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6934000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9180000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1664000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
91091000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
27253000
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1403000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48026000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
18170000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
55000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5457000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2470000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
8581000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
5384000
CY2020 pstx Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
-134000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
755000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3211000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1715000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
224000
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2019Q4 pstx Lessee Operating Lease Commencement Date
LesseeOperatingLeaseCommencementDate
2020-07-29
CY2019Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2029-12-31
CY2019Q4 pstx Additional Tenant Reimbursements
AdditionalTenantReimbursements
1500000
CY2019Q4 us-gaap Security Deposit
SecurityDeposit
300000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2020Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2019Q4 us-gaap Defined Contribution Plan Tax Status Extensible List
DefinedContributionPlanTaxStatusExtensibleList
us-gaap:QualifiedPlanMember
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-129775000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-86527000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4859729
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30143095
CY2019 pstx Effective Income Tax Rate Reconciliation Permanent Adjustments
EffectiveIncomeTaxRateReconciliationPermanentAdjustments
43000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
956000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
428000
CY2020 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
10735000
CY2019 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
5828000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
7101000
CY2020Q4 pstx Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
8388000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
982000
CY2020 pstx Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
2445000
CY2019 pstx Effective Income Tax Rate Reconciliation Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedTaxBenefits
1643000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-27000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1151000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
100216000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49635000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
43756000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13574000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
55000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43061000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25896000
CY2020Q4 pstx Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1558000
CY2019Q4 pstx Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1706000
CY2020Q4 pstx Deferred Tax Assets Grant Income
DeferredTaxAssetsGrantIncome
6648000
CY2019Q4 pstx Deferred Tax Assets Grant Income
DeferredTaxAssetsGrantIncome
5483000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1855000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
65058000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33279000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
15727000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
915000

Files In Submission

Name View Source Status
0001564590-21-012509-index-headers.html Edgar Link pending
0001564590-21-012509-index.html Edgar Link pending
0001564590-21-012509.txt Edgar Link pending
0001564590-21-012509-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gvjhxilkcdry000001.jpg Edgar Link pending
gvjhxilkcdry000002.jpg Edgar Link pending
gvjhxilkcdry000003.jpg Edgar Link pending
gvjhxilkcdry000004.jpg Edgar Link pending
gvjhxilkcdry000005.jpg Edgar Link pending
gvjhxilkcdry000006.jpg Edgar Link pending
gvjhxilkcdry000007.jpg Edgar Link pending
gvjhxilkcdry000008.jpg Edgar Link pending
gvjhxilkcdry000009.jpg Edgar Link pending
gvjhxilkcdry000010.jpg Edgar Link pending
gvjhxilkcdry000011.jpg Edgar Link pending
gvjhxilkcdry000012.jpg Edgar Link pending
gvjhxilkcdry000013.jpg Edgar Link pending
gvjhxilkcdry000014.jpg Edgar Link pending
gvjhxilkcdry000015.jpg Edgar Link pending
gvjhxilkcdry000016.jpg Edgar Link pending
gvjhxilkcdry000017.jpg Edgar Link pending
gvjhxilkcdry000018.jpg Edgar Link pending
gvjhxilkcdry000019.jpg Edgar Link pending
gvjhxilkcdry000020.jpg Edgar Link pending
gvjhxilkcdry000021.jpg Edgar Link pending
gvjhxilkcdry000022.jpg Edgar Link pending
gvjhxilkcdry000023.jpg Edgar Link pending
gvjhxilkcdry000024.jpg Edgar Link pending
gvjhxilkcdry000025.jpg Edgar Link pending
gvjhxilkcdry000026.jpg Edgar Link pending
gvjhxilkcdry000027.jpg Edgar Link pending
gvjhxilkcdry000028.jpg Edgar Link pending
gvjhxilkcdry000029.jpg Edgar Link pending
gvjhxilkcdry000030.jpg Edgar Link pending
gvjhxilkcdry000031.jpg Edgar Link pending
gvjhxilkcdry000032.jpg Edgar Link pending
gvjhxilkcdry000033.jpg Edgar Link pending
gvjhxilkcdry000034.jpg Edgar Link pending
gvjhxilkcdry000035.jpg Edgar Link pending
gvjhxilkcdry000036.jpg Edgar Link pending
gvjhxilkcdry000037.jpg Edgar Link pending
gvjhxilkcdry000038.jpg Edgar Link pending
gvjhxilkcdry000039.jpg Edgar Link pending
gvjhxilkcdry000040.jpg Edgar Link pending
gvjhxilkcdry000041.jpg Edgar Link pending
gvjhxilkcdry000042.jpg Edgar Link pending
gvjhxilkcdry000043.jpg Edgar Link pending
gvjhxilkcdry000044.jpg Edgar Link pending
pstx-10k_20201231.htm Edgar Link pending
pstx-20201231.xml Edgar Link completed
pstx-20201231.xsd Edgar Link pending
pstx-20201231_cal.xml Edgar Link unprocessable
pstx-20201231_def.xml Edgar Link unprocessable
pstx-20201231_lab.xml Edgar Link unprocessable
pstx-20201231_pre.xml Edgar Link unprocessable
pstx-ex211_718.htm Edgar Link pending
pstx-ex231_845.htm Edgar Link pending
pstx-ex311_9.htm Edgar Link pending
pstx-ex312_8.htm Edgar Link pending
pstx-ex321_7.htm Edgar Link pending
pstx-ex322_6.htm Edgar Link pending
pstx-ex46_717.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending